Badania przesiewowe w kierunku raka jajnika u starszych pacjentek (badanie przesiewowe PLCO)
Próba przesiewowa raka prostaty, płuc, jelita grubego i jajnika (PLCO).
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
PRIMARY OBJECTIVES:
I. To determine whether screening with CA125 and transvaginal ultrasound (TVU) can reduce mortality from ovarian cancer in women aged 55-74 at entry.
SECONDARY OBJECTIVES:
I. To assess screening variables, other than mortality, for each of the interventions including sensitivity, specificity, and positive predictive value.
II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as intermediate endpoints.
IV. To conduct biomolecular and genetic research into factors associated with cancer carcinogenesis and promotion, as well as the early detection of these factors.
OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender, and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms (control vs screening).
ARM I (Control): Participants receive standard medical care. Participants complete a Diet History Questionnaire (DHQ) at baseline.
ARM II (Ovarian Screening): Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an ovarian palpation exam (OVR, discontinued in December 1998) and TVU at baseline and annually for 3 years. A scheduling and tracking procedure is implemented to ensure regular attendance at repeat screens for participants screened negative or for those who are designated suspicious or positive at screening but for whom subsequent diagnostic procedures do not reveal ovarian cancer (follow-up diagnostic procedures are through their own medical care environment). Participants diagnosed with ovarian cancer via a screening test are referred for treatment in accordance with current accepted practice for appropriate stage of disease, patient age, and medical condition; a procedure is provided for contact with qualified medical personnel to insure appropriate therapy.
Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH] questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.
After completion of screening, participants are followed up for at least 13 years.
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Maryland
-
Bethesda, Maryland, Stany Zjednoczone, 20892
- National Institutes of Health Clinical Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Exclusion Criteria:
-
Women who at the time of randomization are less than 55 or greater than or equal to 75 years of age
-
Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer
-
Individuals with known prior cancer of the colon, rectum, lung, or ovary
- This includes primary or metastatic PLCO cancers
-
Individuals with previous surgical removal of the entire colon or one lung
- Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason.
-
Individuals who are participating in another cancer screening or cancer primary prevention trial
-
Prior to April 1, 1999 women were excluded from the trial if they were currently taking or had taken Tamoxifen or Evista\Raloxifene in the past 6 months. As of April 1999 based on a decision from the PLCO Ovary Subcommittee, women who have or are currently taking Tamoxifen or Evista\Raloxifene are not excluded from participation.
-
Individuals who are unwilling or unable to sign the informed consent form
-
Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Ekranizacja
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Brak interwencji: Control
Participants receive standard medical care. Participants complete a DHQ at baseline. |
|
|
Aktywny komparator: Ovarian Screening
Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial. |
Correlative studies Undergo questionnaire assessments Undergo TVU
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Ovarian Cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers)
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Ovarian Cancer Death Rates (Including Primary Peritoneal and Fallopian Tube Cancers)
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Deaths From All Causes
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Death Rates From All Causes
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Ovarian Cancer Incidence (Including Primary Peritoneal and Fallopian Tube Cancers)
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer diagnoses confirmed by medical record abstraction. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Ovarian Cancer Incidence Rates (Including Primary Peritoneal and Fallopian Tube Cancers).
Ramy czasowe: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
Ovarian cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as ovarian cancer diagnoses divided by person years at risk for ovarian cancer. |
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
|
|
Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test
Ramy czasowe: One year from screening examination
|
Number of positive screens with complications |
One year from screening examination
|
|
T0 (Baseline) CA-125 Screening Results
Ramy czasowe: T0 (at study entry)
|
Cancer Antigen 125 (CA-125) result. |
T0 (at study entry)
|
|
T0 (Baseline) TVU Screening Results
Ramy czasowe: T0 (at study entry)
|
Transvaginal Ultrasound (TVU) result. |
T0 (at study entry)
|
|
T1 CA-125 Screening Results
Ramy czasowe: T1 (one year after entry)
|
Cancer Antigen 125 (CA-125) result. |
T1 (one year after entry)
|
|
T1 TVU Screening Results
Ramy czasowe: T1 (one year after entry)
|
Transvaginal Ultrasound (TVU) result. |
T1 (one year after entry)
|
|
T2 CA-125 Screening Results
Ramy czasowe: T2 (two years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T2 (two years after entry)
|
|
T2 TVU Screening Results
Ramy czasowe: T2 (one year after entry)
|
Transvaginal Ultrasound (TVU) result. |
T2 (one year after entry)
|
|
T3 CA-125 Screening Results
Ramy czasowe: T3 (three years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T3 (three years after entry)
|
|
T3 TVU Screening Results
Ramy czasowe: T3 (three years after entry)
|
Transvaginal Ultrasound (TVU) result. |
T3 (three years after entry)
|
|
T4 CA-125 Screening Results
Ramy czasowe: T4 (four years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T4 (four years after entry)
|
|
T5 CA-125 Screening Results
Ramy czasowe: T5 (five years after entry)
|
Cancer Antigen 125 (CA-125) result. |
T5 (five years after entry)
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Christine D Berg, National Cancer Institute (NCI)
Publikacje i pomocne linki
Publikacje ogólne
- Jiang Y, Xie Q, Chen R. Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results From a Prospective Cohort Study. Clin Breast Cancer. 2022 Feb;22(2):e206-e213. doi: 10.1016/j.clbc.2021.06.010. Epub 2021 Jun 26.
- Wang K, Wu Q, Li Z, Reger MK, Xiong Y, Zhong G, Li Q, Zhang X, Li H, Foukakis T, Xiang T, Zhang J, Ren G. Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study. Clin Nutr. 2021 May;40(5):3370-3378. doi: 10.1016/j.clnu.2020.11.009. Epub 2020 Nov 16.
- Malcomson FC, Shams-White MM, Reedy J, Huang WY, Moore SC, Loftfield E. Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and risk of lifestyle-related cancers in the prostate, lung, colorectal, and ovarian cancer screening trial. BJC Rep. 2025 Nov 19;3(1):81. doi: 10.1038/s44276-025-00195-6.
- Fan Z, Zhang Y, Yao Q, Liu X, Duan H, Liu Y, Sheng C, Lyu Z, Yang L, Song F, Huang Y, Song F. Effects of joint screening for prostate, lung, colorectal, and ovarian cancer - results from a controlled trial. Front Oncol. 2024 Apr 29;14:1322044. doi: 10.3389/fonc.2024.1322044. eCollection 2024.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Szacowany)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby narządów płciowych
- Choroby układu hormonalnego
- Nowotwory układu moczowo-płciowego
- Nowotwory według lokalizacji
- Nowotwory
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Choroby narządów płciowych, kobiety
- Nowotwory gruczołów dokrewnych
- Choroby jajników
- Choroby przydatków
- Nowotwory narządów płciowych, kobiety
- Zaburzenia gonad
- Nowotwory jajnika
- Zjawiska fizyczne
- Promieniowanie
- Promieniowanie, nieonizujące
- Fale ultradźwiękowe
- Dźwięk
- Wysokoenergetyczne fale uderzeniowe
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- NCI-2012-01758
- CDR0000078532
- NCI-P93-0050
- PLCO-1
- NCI-2012-01758 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- PLCO-Ovarian (Inny identyfikator: National Cancer Institute)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .